

ASX / Media Release

AdAlta to present at two new drug therapy conferences next week

MELBOURNE, Australia, 16 September, 2016: AdAlta Limited (ASX: 1AD), the biotechnology company focused on advancing its lead i-body candidate towards clinical development today announced Chief Scientific Officer Dr Mick Foley will present at the Cambridge Healthtech Institute's 4th Annual Targeting Ocular Disorders conference on **Wednesday September 21** as part of the 14th Annual Discovery of Target conference where he will also present on **Thursday September 22** at the Westin Boston Waterfront Hotel in Boston MA USA.

The prestigious international event provides a platform to discuss novel targets and disease pathways, the latest drug delivery methods, and the most promising emerging therapies.

Dr Foley will present the data on AdAlta's lead candidate AD-114 for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

A copy of the presentations made by Dr Foley will be available on the company's website www.adalta.com.au

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

The i-body is a human analogue of the antigen binding domain of the shark antibody, which combines the advantages of monoclonal antibodies (high target specificity and affinity) with the beneficial stability features of small molecules. In addition to stability, the i-body has a long binding loop that is a feature of shark antibodies not present in either human or next generation antibodies. This feature enables the i-body to recognise and bind to a diverse range of different therapeutically-relevant drug targets, including those that are difficult/intractable to access by current antibody therapies. These include clinically important targets such as G-protein coupled receptors (GPCRs) and ion channels.

AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. AD-114 has strong pre-clinical results for IPF, demonstrating both ant-fibrotic and anti-inflammatory activity in human lung tissue and indicating greater efficacy than existing approved IPF drugs.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au

At the Company

Sam Cobb
Chief Executive Officer
AdAlta Limited
Tel: +61 (0) 3 9479 5159
E: s.cobb@adalta.com.au

Media (Australia)

Andrew Geddes
Tel: +61 (0) 408 677 734
E: adalta@instinctif.com

Media (International)

Sue Charles/Daniel Gooch
Tel: +44 (0) 20 7866 7905
E: adalta@instinctif.com